Dementia (Diagnosis)
Conditions
Brief summary
This prospective study aims: 1. to compare cognitive performance in different clinical groups of participants with mild cognitive impairment (MCI) or mild dementia \[Alzheimer's Disease (AD), Vascular Cognitive Impairment (VCI) and Fronto-temporal Dementia (FTD)\] to determine whether scores reveal differential profiles between the groups, 2. to demonstrate differences in imaging markers between different dementia syndromes and healthy volunteers using ultra high-field MRI at 7T.
Detailed description
The imaging arm of the study include: 1. to demonstrate differences in brain iron levels between different dementia syndromes and healthy volunteers using ultra high-field MRI, quantitative susceptibility mapping (QSM) at 7T. 2. to demonstrate variations in the resting oxygen usage as an important biomarker to discriminate between different dementia syndromes. 3. to demonstrate cerebral blood flow changes in the brain, particularly in the hippocampus region, and its correlation with different dementia syndromes using Arterial Spin Labelling MRI technique. 4. to demonstrate increased blood brain barrier leakage in the brain, particularly in the hippocampus region, and its correlation with Alzheimer's Disease (AD) and Vascular Cognitive Impairment (VCI) using a new dynamic contrast-enhanced MRI (DCE-MRI) technique.
Interventions
DIAGNOSTIC_TESTCognitive assessments
Cognitive assessment and MRI at 3T and/or 7T
Sponsors
Nottingham University Hospitals NHS Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ability to give informed consent. 2. Either pathological, genetic or imaging biomarker evidence to suggest Fronto-temporal Lobar Degeneration, Alzheimer's Disease or Vascular Cognitive Impairment, or defined clinical diagnoses.
Exclusion criteria
1. Lack of mental capacity to consent to study involvement. 2. Not speaking English before age 5 years. 3. Learning disability. 4. MRI contraindications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neurocognitive scales on Birmingham Cognitive Screen (BCoS) Scores | Through study completion (an average of one year) | cognitive sub scores in relation to clinical phenotype |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Structural imaging changes on MRI at 3T | Through study completion (an average of one year) | Structural volume loss |
| Susceptibility weighted mapping at 7T | Through study completion (an average of one year) | Quantitative Susceptibility Mapping |
Countries
United Kingdom
Contacts
Primary ContactAkram Dr Hosseini
Backup ContactPauline Hyman-Taylor
Outcome results
None listed